Kantipur Pharmaceuticals Lab Limited to Issue Ordinary Shares (IPO) to the Public
Author
NEPSE trading
Kantipur Pharmaceuticals Lab Limited is preparing to issue ordinary shares (IPO) to the general public. To proceed with the share issuance, the company has appointed Muktinath Capital as the sales manager.
Key Highlights:
IPO Issuance: The company plans to sell 1.1 million ordinary shares, which is 14.86% of its issued capital, to the public.
Company's Establishment and Purpose: Established in 2018, Kantipur Pharmaceuticals Lab has received a production and marketing registration certificate from the Department of Drug Administration. The company is engaged in the production and distribution of veterinary medicines and nutritional supplements.
Production and Market Presence: The company currently holds distribution certificates for 13 medicines and is distributing them in the Nepali market. Additionally, it is also producing and distributing 21 other nutritional supplements.
Special Feature: This is the first pharmaceutical company in the veterinary medicine industry to issue shares to the general public.
Signing of the Agreement: The IPO issuance agreement was signed by Navaraj Paudyal, Director of Kantipur Pharmaceuticals Lab, and Kabindra Dhwaj Joshi, CEO of Muktinath Capital.
The decision to issue an IPO is expected to increase public participation in the veterinary pharmaceutical industry.
